Brompheniramine with Sustained-Release Pseudoephedrine Dosing
For adults and adolescents 12 years and older, the recommended dose is one sustained-release tablet (typically containing 12 mg brompheniramine with 120 mg pseudoephedrine) every 12 hours, not to exceed 2 tablets in 24 hours. This dosing is weight-independent for this age group and applies uniformly to adolescents 12-17 years regardless of body weight 1.
Standard Dosing Regimen
The FDA-approved dosing for brompheniramine-pseudoephedrine combinations follows a straightforward age-based schedule 1:
For sustained-release formulations:
- Adults and children ≥12 years: One tablet every 12 hours (maximum 2 tablets/24 hours)
- The typical sustained-release tablet contains 12 mg brompheniramine maleate and 120 mg pseudoephedrine sulfate
For immediate-release liquid formulations (when sustained-release is not appropriate):
- Adults and children ≥12 years: 10 mL every 4 hours (maximum 6 doses/24 hours)
- Children 6 to <12 years: 5 mL every 4 hours (maximum 6 doses/24 hours)
- Children 2 to <6 years: 2.5 mL every 4 hours (maximum 6 doses/24 hours)
Critical Considerations for Adolescents
Weight-based adjustments are NOT recommended for adolescents 12-17 years with this combination product. The evidence shows that while weight-normalized doses may be lower in individuals with higher body weight, the absolute doses remain consistent across the age group 2, 3. Bioavailability studies demonstrate that the sustained-release formulation maintains therapeutic levels effectively when dosed every 12 hours regardless of body weight variations within the adolescent population 4, 2.
Important Safety Caveats
Do not use in children under 6 years without physician guidance, as the FDA Pediatric Advisory Committee has raised significant safety concerns about OTC cough and cold medications in young children, with 69 reported fatalities associated with antihistamines (including brompheniramine) in children ≤6 years between 1969-2006 5.
Avoid in patients taking SSRIs or other serotonergic medications. A recent case report documented serotonin syndrome in a patient on sertraline who took Bromfed DM (containing brompheniramine, pseudoephedrine, and dextromethorphan), with symptoms developing within 3 days 6. The combination of first-generation antihistamines with serotonergic drugs poses a real risk even at therapeutic doses.
Monitor cardiovascular parameters in all patients, particularly those with hypertension or cardiac conditions. Pseudoephedrine can cause tachycardia, hypertension, and cardiac arrhythmias, especially in toxic doses 1, 7.
Food Effects
Food has minimal impact on bioavailability—a high-fat meal slightly shortens time to maximum concentration for pseudoephedrine but does not significantly alter overall absorption of either component 4. Patients may take the medication with or without food based on tolerability.